Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Past Presentation MaterialsConference on FY2026.12 Q1 Financial Results
FY2026 Q1 Overview
Dr. Osamu Okuda,
President & CEO
FY2026 Q1 Overview of Development Pipeline
Tsukasa Kusano,
Executive Vice President, Head of Project & Lifecycle Management Unit
FY2026 Q1 Consolidated Financial Overview (Core)
Iwaaki Taniguchi,
Director, Executive Vice President & CFO
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2025(Integrated Report)
Past Annual Report
What's New
-
Annual Report 2025
-
Events & Presentations has been updated with the Date of Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy
-
Script (including Q&A) for Conference on FY2026.12 Q1 Financial Results
-
Conference on FY 2026.12 Q1 Financial Results
-
Financial Results for First Quarter of Fiscal Year 2026 (Jan-Mar 2026)
-
Chugai Receives “The Imperial Invention Prize,” the Highest Honor of the FY2026 National Commendation for Invention — Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research —
-
Organizational and Personnel Changes
-
Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients
-
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors
-
Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
